psychedelics investing Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
psychedelics investing Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
psychedelics investing Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
psychedelics investing Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
psychedelics investing Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
